A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

NCT02891603 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Graft Vs Host Disease
GVHD

Interventions

DRUG: Pacritinib
DRUG: Sirolimus
DRUG: Tacrolimus
PROCEDURE: Allogenic hematopoietic cell transplant (alloHCT)

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]